Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by houbahopon Mar 04, 2023 6:55am
113 Views
Post# 35319021

RE:RE:RE:RE:RE:RE:RE:RE:More options

RE:RE:RE:RE:RE:RE:RE:RE:More options Well, it looks like it is the beginning of the end for Theratechnologies.
Despite the increase in revenues, they are burning cash like never before and the lenders are starting to amend the terms of the credit facility.
The company is signaling the possibility of not being able to continue as a going concern.
I think it's the first time I see this in its 25 years history.

I have not find any material plan to reduce the huge budget in:

Selling: $39m
General & Admin. : $17m
R&D: $37m

And at last but not the least, they gave themselves millions of options to keep them happy while the ship is sinking.

Good luck for the ones staying in the boat as shareholders!
Some will pay the price for reelecting members of this Board of Directors.



<< Previous
Bullboard Posts
Next >>